Effect of Shotblocker in Reducing Intramuscular Injection Pain in Adult Patients

NCT ID: NCT06624761

Last Updated: 2024-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-14

Study Completion Date

2025-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blind study aimed to determine the effect of ShotBlocker on IMI pain in adult patients who received diclofenac sodium and metamizole sodium as IMI in the emergency department. The main question(s) it aims to answer are as follows:

• \[Is there a difference between the pain score averages between the intervention group and the control group after ShotBlocker? Participants \[Participants in both groups are individuals who applied to the emergency department and received IM injections according to the doctor\'s order.\] If there is a comparison group: Researchers will make a comparison with the control group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is planned to be conducted between October 2024 and December 2024. The population of the study will consist of adult patients who have applied to the emergency department of a state hospital in Turkey between October 2024 and December 2024 due to the use of previously prescribed drugs (diclofenac sodium and metamizole sodium) or who need to be administered IMI diclofenac sodium and metamizole sodium upon the order of the emergency room physician. The minimum sample size expected to complete the data collection form of the study was calculated with G power analysis at a 95% confidence level before the data collection phase. Accordingly, the sample size required for the study was determined as 25 for each group, with an alpha value of 0.01, an effect size of 1.583, and a theoretical power of 99% \[23\]. In case of sample loss during the study, it was planned to take 20% more samples than the calculated sample and to include 30 people in each group (with and without ShotBlocker).

As data collection tools; Personal and Applied Drug Information Form and Visual Analog Scale will be used. Personal Information Form will consist of 8 questions in total, 7 of which include the patients' introductory characteristics (age, gender, height, weight, fear of injection) and 1 question including the name of the drug. In addition to this form, Visual Analog Scale (VAS) is used to measure the pain perceived by the person. In this scale, the person can indicate his/her own pain by drawing a line, putting a dot or pointing between the part where there is no pain (zero) on one end of the ruler and the part where there is the most severe pain (10 cm) on the other end. The distance from the point where there is no pain to the point marked by the person is measured in centimeters and the value found indicates the person's pain intensity. In the VAS scale, 0-44 mm reflects mild pain, 45-74 mm reflects moderate pain and 75-100 mm reflects severe pain.

Research Application Procedure Step 1: Before starting the application, a preliminary interview will be conducted with practitioners who are not included in the study and who work as nurses in the emergency department. Information will be provided about the purpose of the study and the scale to be used. It will also be stated that these forms will be filled out by patients who received diclofenac sodium and metamizole sodium as IMI from the ventrogluteal region, used ShotBlocker during this period and met the research criteria.

Step 2: VAS will be applied to the patients immediately after the application. Step 3: VAS will also be applied to patients in the control group who received diclofenac sodium and metamizole sodium as IMI from the ventrogluteal region, did not use ShotBlocker during this period and met the research criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients Above 18 Years

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

There will be 2 groups (ShotBlocker and control )
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ShotBlocker

ShotBlocker will be applied to the experimental group.

Group Type EXPERIMENTAL

ShotBlocker

Intervention Type DEVICE

A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.

Control group

no intervention will be made

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ShotBlocker

A randomized study investigating ShotBlocker in painkillers containing different active ingredients could not be found.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 and over who speak Turkish,
* Who have signed the informed consent form,
* Who are admitted to the emergency room for prescription drug use or who are planned to use diclofenac sodium and metamizole sodium as IMI upon the directive of the emergency room physician will constitute.

Exclusion Criteria

* Pregnant women,
* Those with psychiatric disorders,
* Those with hearing or vision problems,
* Those who applied to the red area of the emergency room,
* Those with impaired consciousness,
* Those with secondary injuries and infections at the injection site,
* Those who have previously received an injection at the same site within the last 24 hours, -Those who did not sign the informed consent form for the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Toros University

OTHER

Sponsor Role collaborator

Yağmur SÜRMELİ

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yağmur SÜRMELİ

LECTURER DR.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

YAGMUR SÜRMELI, DR.

Role: STUDY_DIRECTOR

Toros University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toros State Hospital

Mersin, Adana, Mersin, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

YAGMUR SURMELI, DR.

Role: CONTACT

+905385701923

BEHİRE SANÇAR, Dr.

Role: CONTACT

+905385701923

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

TOROS STATE HOSPITAL STATE HOSPITAL

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-79438647-108-48697 TU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.